Anemia in many XLSA patients responds variably to supplementation with pyridoxine (vitamin B6) which is converted into pyridoxal 5‐phosphate (PLP), the active cofactor essential for ALAS2 activity. Here, ALAS2 is linked to anemia (phenotype).